pyridostigmine bromide has been researched along with Scleroderma, Systemic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahuja, NK; Clarke, JO; McMahan, ZH; Mische, L; Wigley, FM | 1 |
| Ajmani, HS; Bhalla, R; Lazarevic, MB; Skosey, JL; Swedler, WI | 1 |
2 other study(ies) available for pyridostigmine bromide and Scleroderma, Systemic
| Article | Year |
|---|---|
Pyridostigmine for the treatment of gastrointestinal symptoms in systemic sclerosis.
Topics: Adult; Aged; Female; Gastrointestinal Agents; Gastrointestinal Diseases; Gastrointestinal Motility; Humans; Male; Middle Aged; Pyridostigmine Bromide; Retrospective Studies; Scleroderma, Systemic; Treatment Outcome | 2018 |
Myasthenia gravis and scleroderma.
Topics: Adult; Antibodies, Antinuclear; Female; Humans; Myasthenia Gravis; Prednisone; Pyridostigmine Bromide; Scleroderma, Systemic | 1993 |